miR-664 was predicted to target the CDC73 tumor suppressor gene, whose germinal inactivating mutations are responsible for the hyperparathyroidism-jaw tumor syndrome [61] and somatic mutations have been associated with the development of sporadic parathyroid carcinoma [62], and the CDKN2C tumor suppressor gene encoding the p18ink4c, an inhibitor of the cyclin kinases CDK4 and CDK6, that negatively controls the cell cycle G1 progression. The gene discussed is CDKN2C; the disease is parathyroid gland carcinoma.